BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38246041)

  • 1. History of autoimmune disease and long-term survival of epithelial ovarian cancer: The extreme study.
    Hannibal CG; Kjaer SK; Galanakis M; Hertzum-Larsen R; Maltesen T; Baandrup L
    Gynecol Oncol; 2024 Mar; 182():1-6. PubMed ID: 38246041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer: The Extreme study.
    Duus AH; Hannibal CG; Baandrup L; Zheng G; Galanakis M; Maltesen T; Hertzum-Larsen R; Mørch LS; Kjær SK
    Int J Cancer; 2024 Jul; 155(1):19-26. PubMed ID: 38532545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival of nonlocalized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis: The extreme study.
    Baandrup L; Galanakis M; Hannibal CG; Dehlendorff C; Hertzum-Larsen R; Mørch LS; Kjaer SK
    Int J Cancer; 2022 Nov; 151(9):1512-1522. PubMed ID: 35716136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer ꟷ The Extreme study.
    Baandrup L; Dehlendorff C; Hertzum-Larsen R; Hannibal CG; Kjaer SK
    Gynecol Oncol; 2021 May; 161(2):458-462. PubMed ID: 33583579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries.
    Crafton SM; Cohn DE; Llamocca EN; Louden E; Rhoades J; Felix AS
    Cancer; 2020 Mar; 126(6):1217-1224. PubMed ID: 31774553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
    Baandrup L
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).
    Sharma A; Apostolidou S; Burnell M; Campbell S; Habib M; Gentry-Maharaj A; Amso N; Seif MW; Fletcher G; Singh N; Benjamin E; Brunell C; Turner G; Rangar R; Godfrey K; Oram D; Herod J; Williamson K; Jenkins H; Mould T; Woolas R; Murdoch J; Dobbs S; Leeson S; Cruickshank D; Fourkala EO; Ryan A; Parmar M; Jacobs I; Menon U
    Ultrasound Obstet Gynecol; 2012 Sep; 40(3):338-44. PubMed ID: 22911637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.
    Lawal AO; Musekiwa A; Grobler L
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD009620. PubMed ID: 23740789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Socioeconomic status and epithelial ovarian cancer survival in Sweden.
    Weiderpass E; Oh JK; Algeri S; Bellocco R
    Cancer Causes Control; 2014 Aug; 25(8):1063-73. PubMed ID: 24906473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
    Ekmann-Gade AW; Høgdall CK; Seibæk L; Noer MC; Fagö-Olsen CL; Schnack TH
    Gynecol Oncol; 2022 Jan; 164(1):120-128. PubMed ID: 34716025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014.
    Wu SG; Li FY; Lei J; Hua L; He ZY; Zhou J
    Med Sci Monit; 2020 Feb; 26():e920531. PubMed ID: 32008036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
    Staples JN; Peres LC; Camacho F; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Schildkraut JM
    Gynecol Oncol; 2020 Jul; 158(1):123-129. PubMed ID: 32362566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
    Lawrie TA; Rabbie R; Thoma C; Morrison J
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Risk of Epithelial Ovarian Cancer of Women With Endometriosis May be Varied Greatly if Diagnostic Criteria Are Different: A Nationwide Population-Based Cohort Study.
    Lee WL; Chang WH; Wang KC; Guo CY; Chou YJ; Huang N; Huang HY; Yen MS; Wang PH
    Medicine (Baltimore); 2015 Sep; 94(39):e1633. PubMed ID: 26426652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary inflammatory index and risk of epithelial ovarian cancer in African American women.
    Peres LC; Bandera EV; Qin B; Guertin KA; Shivappa N; Hebert JR; Abbott SE; Alberg AJ; Barnholtz-Sloan J; Bondy M; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Camacho F; Wang F; Schildkraut JM
    Int J Cancer; 2017 Feb; 140(3):535-543. PubMed ID: 27727481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study.
    Bešević J; Gunter MJ; Fortner RT; Tsilidis KK; Weiderpass E; Onland-Moret NC; Dossus L; Tjønneland A; Hansen L; Overvad K; Mesrine S; Baglietto L; Clavel-Chapelon F; Kaaks R; Aleksandrova K; Boeing H; Trichopoulou A; Lagiou P; Bamia C; Masala G; Agnoli C; Tumino R; Ricceri F; Panico S; Bueno-de-Mesquita HB; Peeters PH; Jareid M; Quirós JR; Duell EJ; Sánchez MJ; Larrañaga N; Chirlaque MD; Barricarte A; Dias JA; Sonestedt E; Idahl A; Lundin E; Wareham NJ; Khaw KT; Travis RC; Rinaldi S; Romieu I; Riboli E; Merritt MA
    Br J Cancer; 2015 Dec; 113(11):1622-31. PubMed ID: 26554655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy after surgery for epithelial ovarian cancer.
    Saeaib N; Peeyananjarassri K; Liabsuetrakul T; Buhachat R; Myriokefalitaki E
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012559. PubMed ID: 31989588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.